Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00281216 · ClinicalTrials.gov registry record
Innate and Adaptive Immunity in Individuals Experiencing Chronic Obstructive Pulmonary Disease Exacerbations
A clinical trial, sponsored by University of Michigan.
- Completed
- Registry status
- 10
- Enrollment target
NCT00281216 is a clinical trial that has completed, run by University of Michigan. The registered enrollment target is 10 participants.
The verdict
NCT00281216 has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether there is a statistical association between the changes from baseline in the levels of two cytokines interleukin (IL)-17A and IL-6 in the sputum of patients with chronic obstructive pulmonary disease (COPD) and the severity of acute exacerbations of COPD (AE-COPD). These sputum cytokine levels are taken as measures of the adaptive immune response (IL-17A) and the innate immune response (IL-6), respectively. Sputum will be collected either spontaneously or will be obtained by induction; cytokine levels will be measured by ELISA. The primary analysis, comparisons of sputum cytokine levels between clinical states, will be done using random effects modeling.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2005-09 |
| Est. Completion | 2010-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00281216
The ClinicalTrials.gov registry entry for NCT00281216 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00281216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00281216 about?
NCT00281216 is a clinical study titled "Innate and Adaptive Immunity in Individuals Experiencing Chronic Obstructive Pulmonary Disease Exacerbations". The purpose of this study is to determine whether there is a statistical association between the changes from baseline in the levels of two cytokines interleukin (IL)-17A and IL-6 in the sputum of patients with chronic obstructive pulmonary disease (COPD) and the severity of acute exacerbations of C...
What is the current status of trial NCT00281216?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2005-09. Estimated completion is 2010-09.
Who is sponsoring clinical trial NCT00281216?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.